Filing Flows › Senti Biosciences Holdings (SNTI) › Q1 2026
Senti Biosciences Holdings (SNTI) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Senti Biosciences Holdings (SNTI) reported revenue of $16K for the first quarter 2026 (Q1 2026).
Revenue$16K
Year over year—
Quarter over quarter—
Operating margin—
Net earnings−$4.2M
Senti Biosciences Holdings, Q1 2026: revenue $16K, net loss $4.2M, operating cash flow −$7.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16K | — | — |
| Operating profit | −$4.6M | — | — |
| Net earnings | −$4.2M | — | — |
| Operating cash flow | −$7.5M | — | — |
What changed
Revenue was $16K in Q1 2026.
Operating costs exceeded revenue by $4.6M, an operating margin of -28850.0%. The quarter ended with a net loss of $4.2M.
Operating cash flow was −$7.5M. Non-cash charges added back $688K of depreciation and $1.3M of share-based compensation. Working capital and other items used $5.3M.
Questions
What was Senti Biosciences Holdings' revenue in the first quarter 2026?
Senti Biosciences Holdings (SNTI) reported revenue of $16K for the first quarter 2026 (Q1 2026).